lonhln
GSK plc (LON:GSK)’s revenue in the second quarter rose 13% to £6.9bn, reflecting growth across all segments but particular strength in Specialty Medicines. Excluding a one-off, non-cash £699m charge related to Pfizer Inc. (NYSE:PFE) investments and ViiV Healthcare, operating profits were up 22% to £2.0bn. Higher royalty income and sales growth more than offset the impact from a higher proportion of lower-margin Xevudy (Covid-19 solutions) sales, higher freight costs and commodity prices and increased investment in new product launches. Q2 2022 hedge fund letters, conferences and more Excluding...
ValueWalk
FTSE 100 opens higher following gains in Asia and on Wall Street.Supply concerns see Brent crude edge back up above $103 a barrel.Dollar falls back a little against the euro and the pound.UK leadership battle keeps cost-of-living crisis in focus.Worries remain about European gas supply.Deliveroo PLC (LON:ROO) slashes growth forecasts amid economic headwinds.Johnson Matthey PLC (LON:JMAT) hydrogen gigafactory helps lifts share price.Haleon (LON:HLN) completes its demerger from GSK plc (LON:GSK).Financial Markets Are Getting Hot“The temperature check on the financial markets shows the mercury ri...
ValueWalk
Haleon will list on the LSE at 8am on 18 July in a demerger from GSK plc (LON:GSK).The split will leave shareholders with one share of GlaxoSmithKline and one share of Haleon.With gross assets totalling more than £45 billion it is expected to be the largest listing in Europe in over a decade.Haleon will trade on the London Stock Exchange under the ticker symbol ‘HLN’.Haleon’s Listning On LSESusannah Streeter, senior investment and markets analyst: “This will be the largest London Stock Market listing in a decade, with the new company becoming a big beast with a new skin in the consumer goods w...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら